News
Publications
Multimedia
Conferences
Webcasts
Resources
Subscribe

Spotlight -

Drug Development|

Quality Systems

Michael Verlander

Michael Verlander is technical advisor at PolyPeptide Group.

Articles by Michael Verlander

Control Strategies for Synthetic Therapeutic Peptide APIs Part III: Manufacturing Process Considerations

ByAleksander Swietlow,Michael Verlander,Brian Gregg,Harold Rode,Ivo Eggen,Anita Y. Szajek

May 2nd 2014

USP's Therapeutic Peptides Expert Panel discusses manufacturing processes and impurity control for synthetic peptide APIs.

Control Strategies for Synthetic Therapeutic Peptide APIs Part II: Raw Material Considerations

ByAleksander Swietlow,Michael Verlander,Brian Gregg,Harold Rode,Ivo Eggen,Anita Szajek,Anita Y. Szajek

April 2nd 2014

USP evaluates raw materials used in the chemical synthesis of peptides.

Control Strategies for Synthetic Therapeutic Peptide APIs—Part I: Analytical Consideration

ByAleksander Swietlow,Michael Verlander,Brian Gregg,Harold Rode,Ivo Eggen,Anita Szajek

March 2nd 2014

USP evaluates quality attributes for synthetic peptides.

Latest Updated Articles

Control Strategies for Synthetic Therapeutic Peptide APIs Part II: Raw Material Considerations
Published: April 2nd 2014 | Updated:
Control Strategies for Synthetic Therapeutic Peptide APIs—Part I: Analytical Consideration
Published: March 2nd 2014 | Updated:
Control Strategies for Synthetic Therapeutic Peptide APIs Part III: Manufacturing Process Considerations
Published: May 2nd 2014 | Updated:

© 2025 MJH Life Sciences^®

All rights reserved.